Skip to main content
. Author manuscript; available in PMC: 2024 Nov 6.
Published in final edited form as: Open J Immunol. 2024 Sep;14(3):60–86. doi: 10.4236/oji.2024.143006

Table 2.

(a) single nucleotide polymorphisms (SNPs); (b) simple sequence of repeats (variable number tandem repeats and insertion/deletions); (c) dinucleotide repeats.

(a)

GENE POLYMORPHISM VARIANT ALLELES RISK ALLELE
Dopamine D1 Receptor
DRD1
rs4532 A/G A
Dopamine D2 Receptor
DRD2
rs1800497 A/G
(A1/A2)
A
(A1)
Dopamine D3 Receptor
DRD3
rs6280 C/T C
Dopamine D4 Receptor
DRD4
rs1800955 C/T C
Catechol-O-Methyltransferase
COMT
rs4680 A/G
(Met/Val)
G
(Val)
Mu-Opioid Receptor
OPRM1
rs1799971 A/G
(As/Asp)
G
(Asp)
(b)
GENE POLYMORPHISM VARIANT ALLELES RISK ALLELE

Dopamine D4 Receptor
DRD4
rs761010487 48bp repeat
2R - 11R
≥7R, long form
Dopamine Active Transporter
DAT1
rs28363170 40p repeat
3R - 11R
< 9R
Monoamine Oxidase A
MAOA
rs768062321 30bp repeat
2R - 5R
3.5R, 4R, 5R
Serotonin Transporter
SLC6A4 (5-HTTLPR)
rs4795541,
rs25531
43bp repeat, with SNP
L/XL and S, G/A
S, LG
(c)
GENE POLYMORPHISM VARIANT ALLELES RISK ALLELE

GABA(A) Receptor, Alpha-3
GABRB3
rs764926719 CA dinucleotide repeat
171 – 201bp sized fragments
181